August 12, 2010 / 2:32 PM / in 8 years

UPDATE 1-Tekmira Pharmaceuticals Q2 loss widens

* Q2 loss C$4.2 mln vs C$2.3 mln

* Revenue slumps 40 pct

* Shares fall 7 pct

Aug 12 (Reuters) - Canada’s Tekmira Pharmaceuticals Corp TKM.TO posted a wider loss hurt by increased spending at two of its programs, sending shares down as much as 7 percent.

Tekmira posted a loss of C$4.2 million, that compares to a loss of C$2.3 million.

Revenue from research and development collaborations, licensing fees and milestone payments was C$2.3 million, down from C$3.8 million.

Tekmira said it was completing toxicology studies in preparation for clinical development of TKM-ApoB, a treatment for high cholesterol, and TKM-PLK1, a treatment for solid tumor cancers, weighing down on its results.

Shares of the company were down 2 percent at C$1.70 Thursday morning on the Toronto Stock Exchange. They earlier touched a low of C$1.61. (Reporting by Isheeta Sanghi in Bangalore; Editing by Don Sebastian) ((; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800; Reuters Messaging:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below